These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 23369246)
1. Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection. Habermehl D; Brecht IC; Bergmann F; Welzel T; Rieken S; Werner J; Schirmacher P; Büchler MW; Debus J; Combs SE Radiat Oncol; 2013 Jan; 8():27. PubMed ID: 23369246 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review. Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. Habermehl D; Brecht IC; Bergmann F; Rieken S; Werner J; Büchler MW; Springfeld C; Jäger D; Debus J; Combs SE World J Surg Oncol; 2015 Apr; 13():149. PubMed ID: 25889749 [TBL] [Abstract][Full Text] [Related]
4. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. Hurt CN; Falk S; Crosby T; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T; Mukherjee S Br J Cancer; 2017 May; 116(10):1264-1270. PubMed ID: 28376080 [TBL] [Abstract][Full Text] [Related]
5. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Regine WF; Winter KA; Abrams R; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Rich TA; Willett CG Ann Surg Oncol; 2011 May; 18(5):1319-26. PubMed ID: 21499862 [TBL] [Abstract][Full Text] [Related]
6. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. McDonald AM; Dulaney CR; López-Araujo J; Posey JA; Keene KS; Christein JD; Heslin MJ; Wood TE; Jacob R J Gastrointest Cancer; 2015 Jun; 46(2):149-55. PubMed ID: 25782589 [TBL] [Abstract][Full Text] [Related]
7. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. Wilkowski R; Thoma M; Bruns C; Wagner A; Heinemann V JOP; 2006 Jul; 7(4):349-60. PubMed ID: 16832132 [TBL] [Abstract][Full Text] [Related]
8. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. Kim JS; Lim JH; Kim JH; Im SA; Chie EK; Hwang JH; Kim TY; Bang YJ; Ha SW; Yoon YB Cancer Chemother Pharmacol; 2012 Sep; 70(3):381-9. PubMed ID: 22806305 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Van Buren G; Ramanathan RK; Krasinskas AM; Smith RP; Abood GJ; Bahary N; Lembersky BC; Shuai Y; Potter DM; Bartlett DL; Zureikat AH; Zeh HJ; Moser AJ Ann Surg Oncol; 2013 Nov; 20(12):3787-93. PubMed ID: 23904005 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835 [TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850 [TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. You DD; Lee HG; Heo JS; Choi SH; Choi DW J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512 [TBL] [Abstract][Full Text] [Related]
13. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973 [TBL] [Abstract][Full Text] [Related]
14. Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. Golden DW; Novak CJ; Minsky BD; Liauw SL Radiat Oncol; 2012 Sep; 7():156. PubMed ID: 22974515 [TBL] [Abstract][Full Text] [Related]